Gary Fischetti joined the board of directors of Medcura, which develops LifeGel, according to a May 3 news release.
Mr. Fischetti has more than 35 years of experience in medtech including senior executive roles with Johnson & Johnson’s Ethicon and DePuy Synthes businesses. He’s also on the boards of Anika Therapeutics, Acuitive Technologies, and he’s board chair for Orchid Orthopedic Solutions.
“With his proven leadership at Ethicon Biosurgery and DePuy Spine, Gary brings unmatched expertise in innovation, regulatory strategy, and global commercialization,” Jim Buck, CEO of Medcura said in the release. “His guidance will be invaluable as we advance LifeGel™ through pivotal pre-clinical studies and into human clinical trials, accelerating our path to commercialization into the U.S. and global markets.”
LifeGel is Medcura’s flagship product and is a he first and only absorbable hemostatic agent to receive FDA Breakthrough Device Designation for its non-swelling properties.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
